1Jamal A,Siegel R,Ward E,et al.Cancer statistics.CA Cancer J Clin,2007,57(1):43 -66.
2Hughs MD,He Z,Liu S,et al.Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma:relationship to mutations of the von Hippel-Lindau tumor suppress or gene.Cancer Genet Cytogenet,2003,143 (2):145-153.
3Cohen HT,McGovern FJ.Renal cell carcinoma.N Engl J M ed,2005,353 (23):2477-2490.
5Bukowski RM,Eisen T,Szczylik C,et al.Final results of the randomized phase Ⅲ trial of sorafenib in advanced renal cell carcinoma:Survival and biomarker analysis.ASCO Annual Meeting Proceedings Part Ⅰ.J Clin Oncol,2007; 25(Suppl.18):5023.
6Amato R,Harris P,Dalton M,et al.A phase Ⅱ trial of intra-patient dose -escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC).ASCO Annual Meeting Proceedings Part Ⅰ.J Clin Oncol,2007; 25 (Suppl.):5026.
9Escudier B,Ravaud A,Negrier S,et al.Update on AVOREN trial in metastatic renal cell carcinoma:Efficacy and safety in subgroups of patients and pharmacokinetic analysis.ASCO Annual Meeting Proceedings.J Clin Oncol,2008,26:(Suppl.):5025.
10Hutson TE,Davis ID,Machiels JP,et al.Pazopanib (GW786034)is active in metastatic renal cell carcinoma (RCC):interim result s of a phase Ⅱ randomized discontinuation trial (RDT).J Clin Oncol,2007,25:5031.
